Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

ICHICH guidelineBioequivalenceMedicinesHigh confidenceLast verified October 4, 2026

M9

Biopharmaceutics Classification System-based Biowaivers

Current edition

Step 4, 20 November 2019

About this standard

Gives recommendations for the biopharmaceutics classification of medicines and for waiving bioequivalence studies on that basis.

Recognition by market

Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts

  • United StatesImplemented
    Edition accepted
    -
    National code
    -

    Effective May 11, 2021

  • European UnionImplemented
    Edition accepted
    -
    National code
    EMA/CHMP/ICH/493213/2018

    Effective July 30, 2020

  • United KingdomImplemented
    Edition accepted
    -
    National code
    -

    Effective July 1, 2020

  • JapanImplemented
    Edition accepted
    -
    National code
    PSEHB/PED Notification No. 1225-13

    Effective December 25, 2020

  • ChinaImplemented
    Edition accepted
    -
    National code
    NMPA, China Announcement No. 61 (2021)

    Effective November 7, 2021

  • CanadaImplemented
    Edition accepted
    -
    National code
    File #: 20-109235-116

    Effective August 26, 2020

  • BrazilImplemented
    Edition accepted
    -
    National code
    RDC 749/2022

    Effective September 5, 2022

  • South KoreaImplemented
    Edition accepted
    -
    National code
    -
    1) Standard on Pharmaceutical Equivalnce Study 2) Guideline on Biopharmaceutics Classification System-based Biowaivers

    Effective December 1, 2021

  • SwitzerlandImplemented
    Edition accepted
    -
    National code
    -

    Effective August 1, 2020

  • MexicoNot yet implemented
    Edition accepted
    -
    National code
    -

    Not yet implemented by this regulator.

  • Saudi ArabiaImplemented
    Edition accepted
    -
    National code
    -

    Effective April 15, 2026

  • SingaporeImplemented
    Edition accepted
    -
    National code
    -
    Guidance on Therapeutic Product Registration in Singapore, Appendix 10: Product Interchangeability and Biowaiver Request for Chemical Generic Drug Applications

    Effective April 1, 2022

  • TaiwanImplemented
    Edition accepted
    -
    National code
    Guideline for Biopharmaceutics Classification System-Based Biowaivers

    Effective October 25, 2021

Testing requirements that cite it

Open the market page and its pathway pages for the full requirement, protocol and report content

Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M13A. See all standards.

Not legal or regulatory advice. Check the current official rules before you act. Parts of the approvals data are official open data reused under open licences. Data sources.

LinkedInLinkedInXXYouTubeYouTube